638 related articles for article (PubMed ID: 32672401)
1. Structural insights into the multiple binding modes of Dimethyl Fumarate (DMF) and its analogs to the Kelch domain of Keap1.
Unni S; Deshmukh P; Krishnappa G; Kommu P; Padmanabhan B
FEBS J; 2021 Mar; 288(5):1599-1613. PubMed ID: 32672401
[TBL] [Abstract][Full Text] [Related]
2. Characterization of the modification of Kelch-like ECH-associated protein 1 by different fumarates.
Qu L; Guo M; Zhang H; Chen X; Wei H; Jiang L; Li J; Chen Z; Dai S; Chen Y
Biochem Biophys Res Commun; 2022 May; 605():9-15. PubMed ID: 35306364
[TBL] [Abstract][Full Text] [Related]
3. Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.
Brennan MS; Matos MF; Li B; Hronowski X; Gao B; Juhasz P; Rhodes KJ; Scannevin RH
PLoS One; 2015; 10(3):e0120254. PubMed ID: 25793262
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a Kelch-like ECH-associated protein 1-inhibitory tetrapeptide and its structural characterization.
Sogabe S; Sakamoto K; Kamada Y; Kadotani A; Fukuda Y; Sakamoto JI
Biochem Biophys Res Commun; 2017 May; 486(3):620-625. PubMed ID: 28315327
[TBL] [Abstract][Full Text] [Related]
5. Structural insights into the similar modes of Nrf2 transcription factor recognition by the cytoplasmic repressor Keap1.
Padmanabhan B; Tong KI; Kobayashi A; Yamamoto M; Yokoyama S
J Synchrotron Radiat; 2008 May; 15(Pt 3):273-6. PubMed ID: 18421157
[TBL] [Abstract][Full Text] [Related]
6. Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2).
Tian W; Rojo de la Vega M; Schmidlin CJ; Ooi A; Zhang DD
J Biol Chem; 2018 Feb; 293(6):2029-2040. PubMed ID: 29255090
[TBL] [Abstract][Full Text] [Related]
7. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model.
Tong KI; Katoh Y; Kusunoki H; Itoh K; Tanaka T; Yamamoto M
Mol Cell Biol; 2006 Apr; 26(8):2887-900. PubMed ID: 16581765
[TBL] [Abstract][Full Text] [Related]
8. Activation of Nrf2/Keap1 pathway by oral Dimethylfumarate administration alleviates oxidative stress and age-associated infertility might be delayed in the mouse ovary.
Akino N; Wada-Hiraike O; Isono W; Terao H; Honjo H; Miyamoto Y; Tanikawa M; Sone K; Hirano M; Harada M; Hirata T; Hirota Y; Koga K; Oda K; Fujii T; Osuga Y
Reprod Biol Endocrinol; 2019 Feb; 17(1):23. PubMed ID: 30760288
[TBL] [Abstract][Full Text] [Related]
9. Structure of the Keap1:Nrf2 interface provides mechanistic insight into Nrf2 signaling.
Lo SC; Li X; Henzl MT; Beamer LJ; Hannink M
EMBO J; 2006 Aug; 25(15):3605-17. PubMed ID: 16888629
[TBL] [Abstract][Full Text] [Related]
10. Nuclear factor (erythroid-derived 2)-like 2 (NRF2) drug discovery: Biochemical toolbox to develop NRF2 activators by reversible binding of Kelch-like ECH-associated protein 1 (KEAP1).
Bresciani A; Missineo A; Gallo M; Cerretani M; Fezzardi P; Tomei L; Cicero DO; Altamura S; Santoprete A; Ingenito R; Bianchi E; Pacifici R; Dominguez C; Munoz-Sanjuan I; Harper S; Toledo-Sherman L; Park LC
Arch Biochem Biophys; 2017 Oct; 631():31-41. PubMed ID: 28801166
[TBL] [Abstract][Full Text] [Related]
11. Monoacidic Inhibitors of the Kelch-like ECH-Associated Protein 1: Nuclear Factor Erythroid 2-Related Factor 2 (KEAP1:NRF2) Protein-Protein Interaction with High Cell Potency Identified by Fragment-Based Discovery.
Davies TG; Wixted WE; Coyle JE; Griffiths-Jones C; Hearn K; McMenamin R; Norton D; Rich SJ; Richardson C; Saxty G; Willems HM; Woolford AJ; Cottom JE; Kou JP; Yonchuk JG; Feldser HG; Sanchez Y; Foley JP; Bolognese BJ; Logan G; Podolin PL; Yan H; Callahan JF; Heightman TD; Kerns JK
J Med Chem; 2016 Apr; 59(8):3991-4006. PubMed ID: 27031670
[TBL] [Abstract][Full Text] [Related]
12. Structural and mechanistic insights into the Keap1-Nrf2 system as a route to drug discovery.
Madden SK; Itzhaki LS
Biochim Biophys Acta Proteins Proteom; 2020 Jul; 1868(7):140405. PubMed ID: 32120017
[TBL] [Abstract][Full Text] [Related]
13. Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.
Huerta C; Jiang X; Trevino I; Bender CF; Ferguson DA; Probst B; Swinger KK; Stoll VS; Thomas PJ; Dulubova I; Visnick M; Wigley WC
Biochim Biophys Acta; 2016 Nov; 1860(11 Pt A):2537-2552. PubMed ID: 27474998
[TBL] [Abstract][Full Text] [Related]
14. Nrf2, the Major Regulator of the Cellular Oxidative Stress Response, is Partially Disordered.
Karunatilleke NC; Fast CS; Ngo V; Brickenden A; Duennwald ML; Konermann L; Choy WY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299054
[TBL] [Abstract][Full Text] [Related]
15. Recent progress and applications of small molecule inhibitors of Keap1-Nrf2 axis for neurodegenerative diseases.
Wang J; Cao Y; Lu Y; Zhu H; Zhang J; Che J; Zhuang R; Shao J
Eur J Med Chem; 2024 Jan; 264():115998. PubMed ID: 38043492
[TBL] [Abstract][Full Text] [Related]
16. Recapitulating the Binding Affinity of Nrf2 for KEAP1 in a Cyclic Heptapeptide, Guided by NMR, X-ray Crystallography, and Machine Learning.
Ortet PC; Muellers SN; Viarengo-Baker LA; Streu K; Szymczyna BR; Beeler AB; Allen KN; Whitty A
J Am Chem Soc; 2021 Mar; 143(10):3779-3793. PubMed ID: 33683866
[TBL] [Abstract][Full Text] [Related]
17. Role of human Keap1 S53 and S293 residues in modulating the binding of Keap1 to Nrf2.
Wei S; Pei Y; Wang Y; Guan H; Huang Y; Xing T; Johnson RW; Wang D
Biochimie; 2019 Mar; 158():73-81. PubMed ID: 30576774
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Binding Energy of Keap1 Interaction Motifs in the Nrf2 Antioxidant Pathway and Design of Potential High-Affinity Peptides.
Karttunen M; Choy WY; Cino EA
J Phys Chem B; 2018 Jun; 122(22):5851-5859. PubMed ID: 29745220
[TBL] [Abstract][Full Text] [Related]
19. Emerging Substrate Proteins of Kelch-like ECH Associated Protein 1 (Keap1) and Potential Challenges for the Development of Small-Molecule Inhibitors of the Keap1-Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2) Protein-Protein Interaction.
Zhang Y; Shi Z; Zhou Y; Xiao Q; Wang H; Peng Y
J Med Chem; 2020 Aug; 63(15):7986-8002. PubMed ID: 32233486
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in understanding NRF2 as a druggable target: development of pro-electrophilic and non-covalent NRF2 activators to overcome systemic side effects of electrophilic drugs like dimethyl fumarate.
Satoh T; Lipton S
F1000Res; 2017; 6():2138. PubMed ID: 29263788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
